Phase 3Data readout

Rezdiffra (Resmetirom) (MGL-3196)

Liver disease, Cirrhosis

MDGLMadrigal Pharmaceuticals

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: Rezdiffra (Resmetirom) (MGL-3196)
Development stage: Phase 3
Event type: Data readout
Indication: Liver disease, Cirrhosis

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Rezdiffra (Resmetirom) (MGL-3196) in Liver disease, Cirrhosis. The expected timing is based on the latest available company guidance and may change.

Development notes

MAESTRO-NASH OUTCOMES study. 10/21/24- Enrollment completed. 6/20/25- Received positive CHMP opinion w/ decision in August 2025. 8/5/25- Present data in 2027. 05/20/26:- EASL 2026 May 27-30 posters report two-year F4c analyses, including ANTICIPATE-NASH risk scores. 05/27/26:- EASL 2026 posters showed ANTICIPATE-NASH improvements in F4c OLE; liver events infrequent.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source